Montefiore Medical Center_Investigational Site Number 84032
Welcome,         Profile    Billing    Logout  
 8 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Melamed, Isaac R
NCT04705831: Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Recruiting
4
40
US
Ruconest
IMMUNOe Research Centers
Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19
01/22
01/22
KIDCARES10, NCT04944979: Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients

Recruiting
3
30
Europe, US, RoW
Kedrion IVIG 10%
Kedrion S.p.A.
Primary Immunodeficiency Disease
04/26
10/26
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Recruiting
3
194
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
06/25
11/26
NCT05288504: A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Completed
2
91
US
AVTX-002, CERC-002, AEVI-002, MDGN-002, Placebo
Avalo Therapeutics, Inc.
Non-Eosinophilic Asthma
05/23
05/23
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Completed
2
63
US
TNX-102 SL, Placebo SL Tablet
Tonix Pharmaceuticals, Inc.
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
07/23
07/23
NCT04589403: 1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Recruiting
1
15
US
OPT101, 15-mer peptide
Op-T LLC
Healthy
06/24
06/24
INSPIRE, NCT04288921: Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites

Recruiting
N/A
2000
US
Swab
LumiraDx UK Limited
Influenza, Human, Respiratory Syncytial Virus Infections
09/23
09/23
Lambert, Michele
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Recruiting
3
194
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
06/25
11/26
PINES, NCT03939637: Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Active, not recruiting
3
122
US
Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin
Baylor College of Medicine, Boston Children's Hospital, University of California, San Francisco
Immune Thrombocytopenia
03/25
12/25
ITP-APPS, NCT03810352: Association of Platelet Parameters With Bleeding Severity in Children With ITP

Completed
N/A
95
US
Boston Children's Hospital, Sysmex America, Inc., Children's Hospital Colorado, Children's Hospital of Philadelphia, Baylor College of Medicine, Columbia University, Duke University
Immune Thrombocytopenia
11/23
11/23
Murakhovskaya, Irina
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Recruiting
3
194
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
06/25
11/26
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Recruiting
3
150
Europe, Japan, US, RoW
Ianalumab, VAY736, Eltrombopag, ETB115, Placebo
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
06/25
05/28
APPELHUS, NCT04889430 / 2020-005186-13: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Recruiting
3
50
Europe, Japan, US, RoW
Iptacopan, LNP023
Novartis Pharmaceuticals, Novartis Pharma AG
Atypical Hemolytic Uremic Syndrome
12/25
01/26
VAYHIA, NCT05648968: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Recruiting
3
90
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals
Warm Autoimmune Hemolytic Anemia (wAIHA)
03/26
02/29
NCT04747613: Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Recruiting
3
250
Europe, Japan, US, RoW
Iptacopan, LNP023
Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
01/28
01/28
Townsend, Noelle
NCT05481151: A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Recruiting
3
100
Canada, US
P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
PharmaEssentia
Polycythemia Vera
01/24
12/25
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Recruiting
3
194
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
06/25
11/26
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Recruiting
3
150
Europe, Japan, US, RoW
Ianalumab, VAY736, Eltrombopag, ETB115, Placebo
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
06/25
05/28
VAYHIA, NCT05648968: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Recruiting
3
90
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals
Warm Autoimmune Hemolytic Anemia (wAIHA)
03/26
02/29
EXCEED ET, NCT05482971: A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Recruiting
2
64
Canada, US
Ropeginterferon alfa-2b-njft (P1101), P1101
PharmaEssentia
Essential Thrombocythemia
07/24
12/26

Download Options